Proficio Capital Partners LLC Makes New Investment in TG Therapeutics, Inc. (NASDAQ:TGTX)

Proficio Capital Partners LLC bought a new position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) during the fourth quarter, Holdings Channel reports. The fund bought 10,174 shares of the biopharmaceutical company’s stock, valued at approximately $306,000.

A number of other large investors have also recently added to or reduced their stakes in TGTX. Victory Capital Management Inc. raised its holdings in TG Therapeutics by 24.7% in the 3rd quarter. Victory Capital Management Inc. now owns 32,679 shares of the biopharmaceutical company’s stock valued at $764,000 after buying an additional 6,467 shares during the period. Mutual of America Capital Management LLC acquired a new position in shares of TG Therapeutics during the third quarter worth about $469,000. Thrivent Financial for Lutherans acquired a new stake in TG Therapeutics in the third quarter valued at approximately $2,450,000. Quest Partners LLC purchased a new position in TG Therapeutics in the third quarter valued at $246,000. Finally, Intech Investment Management LLC purchased a new stake in TG Therapeutics during the 3rd quarter worth about $1,129,000. 58.58% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at TG Therapeutics

In other news, CFO Sean A. Power sold 10,021 shares of the company’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $28.53, for a total transaction of $285,899.13. Following the completion of the transaction, the chief financial officer now owns 660,611 shares of the company’s stock, valued at $18,847,231.83. This represents a 1.49 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 10.50% of the company’s stock.

TG Therapeutics Price Performance

TG Therapeutics stock opened at $40.79 on Thursday. TG Therapeutics, Inc. has a 52 week low of $12.93 and a 52 week high of $43.32. The firm has a market capitalization of $6.41 billion, a PE ratio of -407.86 and a beta of 2.30. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27. The firm’s 50-day simple moving average is $33.95 and its 200 day simple moving average is $30.11.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share for the quarter, topping analysts’ consensus estimates of $0.08 by $0.07. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The company had revenue of $108.19 million during the quarter, compared to analysts’ expectations of $100.67 million. On average, equities research analysts predict that TG Therapeutics, Inc. will post 0.08 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on TGTX. HC Wainwright restated a “buy” rating and issued a $55.00 target price on shares of TG Therapeutics in a report on Tuesday, March 4th. StockNews.com raised TG Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, March 4th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $40.67.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.